ATR-12
Netherton Syndrome
Phase 1Active
Key Facts
About azitra
Azitra is a clinical-stage biopharmaceutical company focused on developing precision dermatology treatments by engineering the skin's native microbiome. Its core strategy utilizes a proprietary platform combining a large microbial library, AI/ML screening, and genetic engineering to create live biotherapeutic products and engineered proteins. The company's lead program, ATR-12, targets the rare disease Netherton syndrome, with a pipeline extending to oncology supportive care and common dermatoses.
View full company profile